297 related articles for article (PubMed ID: 31003519)
61. Pharmacological augmentation of endocannabinoid signaling reduces the neuroendocrine response to stress.
Surkin PN; Gallino SL; Luce V; Correa F; Fernandez-Solari J; De Laurentiis A
Psychoneuroendocrinology; 2018 Jan; 87():131-140. PubMed ID: 29065362
[TBL] [Abstract][Full Text] [Related]
62. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors.
Marinelli S; Di Marzo V; Florenzano F; Fezza F; Viscomi MT; van der Stelt M; Bernardi G; Molinari M; Maccarrone M; Mercuri NB
Neuropsychopharmacology; 2007 Feb; 32(2):298-308. PubMed ID: 16760924
[TBL] [Abstract][Full Text] [Related]
63. Endocannabinoid metabolism by cytochrome P450 monooxygenases.
Zelasko S; Arnold WR; Das A
Prostaglandins Other Lipid Mediat; 2015; 116-117():112-23. PubMed ID: 25461979
[TBL] [Abstract][Full Text] [Related]
64. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
65. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure.
Weis F; Beiras-Fernandez A; Sodian R; Kaczmarek I; Reichart B; Beiras A; Schelling G; Kreth S
J Mol Cell Cardiol; 2010 Jun; 48(6):1187-93. PubMed ID: 19931541
[TBL] [Abstract][Full Text] [Related]
66. Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.
Pascual AC; Gaveglio VL; Giusto NM; Pasquaré SJ
Exp Gerontol; 2014 Jul; 55():134-42. PubMed ID: 24768821
[TBL] [Abstract][Full Text] [Related]
67. The skeletal endocannabinoid system: clinical and experimental insights.
Raphael B; Gabet Y
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):237-45. PubMed ID: 26457774
[TBL] [Abstract][Full Text] [Related]
68. The endocannabinoid-CB receptor system: Importance for development and in pediatric disease.
Fride E
Neuro Endocrinol Lett; 2004; 25(1-2):24-30. PubMed ID: 15159678
[TBL] [Abstract][Full Text] [Related]
69. Evidence for CB2 receptor involvement in LPS-induced reduction of cAMP intracellular levels in uterine explants from pregnant mice: pathophysiological implications.
Salazar AI; Carozzo A; Correa F; Davio C; Franchi AM
Mol Hum Reprod; 2017 Jul; 23(7):500-508. PubMed ID: 28460003
[TBL] [Abstract][Full Text] [Related]
70. Role of the endocannabinoid system in the mechanisms involved in the LPS-induced preterm labor.
Bariani MV; Domínguez Rubio AP; Cella M; Burdet J; Franchi AM; Aisemberg J
Reproduction; 2015 Dec; 150(6):463-72. PubMed ID: 26347521
[TBL] [Abstract][Full Text] [Related]
71. Cannabinoid receptors in the kidney.
Hryciw DH; McAinch AJ
Curr Opin Nephrol Hypertens; 2016 Sep; 25(5):459-64. PubMed ID: 27367912
[TBL] [Abstract][Full Text] [Related]
72. Effect of capacitation on the endocannabinoid system of mouse sperm.
Catanzaro G; Battista N; Rossi G; Di Tommaso M; Pucci M; Pirazzi V; Cecconi S; Maccarrone M
Mol Cell Endocrinol; 2011 Aug; 343(1-2):88-92. PubMed ID: 21723369
[TBL] [Abstract][Full Text] [Related]
73. Focusing on OB-OC-MΦ Axis and miR-23a to Explore the Pathogenesis and Treatment Strategy of Osteoporosis.
Ma TL; Zhu P; Ke ZR; Chen JX; Hu YH; Xie J
Front Endocrinol (Lausanne); 2022; 13():891313. PubMed ID: 35909545
[TBL] [Abstract][Full Text] [Related]
74. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.
Sagar DR; Jhaveri MD; Richardson D; Gray RA; de Lago E; Fernández-Ruiz J; Barrett DA; Kendall DA; Chapman V
Eur J Neurosci; 2010 Apr; 31(8):1414-22. PubMed ID: 20384778
[TBL] [Abstract][Full Text] [Related]
75. Analysis in conditional cannabinoid 1 receptor-knockout mice reveals neuronal subpopulation-specific effects on epileptogenesis in the kindling paradigm.
von Rüden EL; Jafari M; Bogdanovic RM; Wotjak CT; Potschka H
Neurobiol Dis; 2015 Jan; 73():334-47. PubMed ID: 25123336
[TBL] [Abstract][Full Text] [Related]
76. Role of the endocannabinoid system in drug addiction.
Manzanares J; Cabañero D; Puente N; García-Gutiérrez MS; Grandes P; Maldonado R
Biochem Pharmacol; 2018 Nov; 157():108-121. PubMed ID: 30217570
[TBL] [Abstract][Full Text] [Related]
77. Cannabinoid signaling and liver therapeutics.
Mallat A; Teixeira-Clerc F; Lotersztajn S
J Hepatol; 2013 Oct; 59(4):891-6. PubMed ID: 23567085
[TBL] [Abstract][Full Text] [Related]
78. Effects of bioactive fatty acid amide derivatives in zebrafish scale model of bone metabolism and disease.
Carnovali M; Ottria R; Pasqualetti S; Banfi G; Ciuffreda P; Mariotti M
Pharmacol Res; 2016 Feb; 104():1-8. PubMed ID: 26707833
[TBL] [Abstract][Full Text] [Related]
79. Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis.
Lowin T; Straub RH
Arthritis Res Ther; 2015 Sep; 17(1):226. PubMed ID: 26343051
[TBL] [Abstract][Full Text] [Related]
80. Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies.
Idris AI
Curr Neuropharmacol; 2010 Sep; 8(3):243-53. PubMed ID: 21358974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
